RETA Reata Pharmaceuticals Inc.

84.91
-0.93  -1%
Previous Close 85.84
Open 86.4
Price To Book -566.07
Market Cap 2,552,053,007
Shares 30,055,977
Volume 259,972
Short Ratio
Av. Daily Volume 213,611

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2019.
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 3 data due 1H 2020.
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 2 data due 2H 2019.
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2 initial data released March 1, 2018 - endpoints not met.
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 1b interim data released December 11, 2017 - 27% ORR.
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 2 primary endpoint met - noted March 22, 2018.
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 3 enrolment has commenced - May 30, 2019.
Bardoxolone - FALCON
Chronic Kidney Disease
Phase 1 initiation announced June 20, 2018. Initial data due 2Q 2019.
RTA 1701
Healthy Volunteers

Latest News

  1. The Reata Pharmaceuticals (NASDAQ:RETA) Share Price Has Soared 359%, Delighting Many Shareholders
  2. Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA)
  3. Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
  4. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  5. Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  6. Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
  7. Reata Announces First Patient Enrolled in Phase 3 FALCON Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  8. Edited Transcript of RETA earnings conference call or presentation 9-May-19 12:00pm GMT
  9. Reata's drug, Bardoxolone, shows promising results for chronic kidney disease
  10. Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Earnings Call Transcript
  11. Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates
  12. Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs
  13. Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference
  14. Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit
  15. Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019
  16. Did Hedge Funds Drop The Ball On Reata Pharmaceuticals, Inc. (RETA) ?
  17. Reata Pharmaceuticals, Inc. (NASDAQ:RETA): When Will It Breakeven?
  18. Reata CEO on drug that shows signs of reversing kidney damage
  19. Edited Transcript of RETA earnings conference call or presentation 28-Feb-19 1:00pm GMT
  20. Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Earnings Conference Call Transcript